MariMed (OTCMKTS:MRMD – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.
Earnings and Valuation
This table compares MariMed and IM Cannabis’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MariMed | $148.60 million | 0.43 | -$16.03 million | ($0.04) | -4.25 |
| IM Cannabis | $36.15 million | 0.91 | -$7.04 million | ($0.80) | -3.09 |
IM Cannabis has lower revenue, but higher earnings than MariMed. MariMed is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
0.2% of MariMed shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 20.6% of MariMed shares are owned by company insiders. Comparatively, 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
MariMed has a beta of 2.8, suggesting that its stock price is 180% more volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
Profitability
This table compares MariMed and IM Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MariMed | -10.97% | -2.75% | -1.06% |
| IM Cannabis | -28.03% | -75.51% | -24.18% |
Analyst Ratings
This is a summary of current ratings for MariMed and IM Cannabis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MariMed | 0 | 0 | 0 | 0 | N/A |
| IM Cannabis | 0 | 0 | 0 | 0 | N/A |
Summary
MariMed beats IM Cannabis on 7 of the 11 factors compared between the two stocks.
About MariMed
(Get Free Report)
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
About IM Cannabis
(Get Free Report)
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for MariMed Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MariMed and related companies with MarketBeat.com’s FREE daily email newsletter.
Be the first to comment